Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Inclusion Criteria:

* Any biopsy or cytologically proven resectable or unresectable primary or secondary (metastatic) malignancy in the lung; this is defined as

  * Tumors whose only remaining residual deposits are confined to the lungs OR
  * Oligometastatic tumors with \> 80% of measurable tumor volume in the target lung In both of the above situations, no clinical evidence of central nervous system (CNS) metastases can exist; oligometastatic disease is difficult to define but would, as a guideline, have only 1-4 loci of disease established in 1-2 organ systems outside the affected lung; exceptions to these guidelines can occur, particularly in cases where sites of metastatic disease are equivocal or so minute that it would not exceed 20% of tumor volume
* Unresectable stage IV non-small cell lung cancer (NSCLC)
* Unresectable stage IIIB NSCLC
* Resectable metastatic sarcoma to lung (thoracoscopically resectable)
* Other malignancies that meet the criteria
* Eastern Cooperative Oncology Group performance status 0-1
* No oxygen needs (oxygen use per standard established criteria for oxygen requirements)
* Modified Borg dyspnea scale \< 5
* Six minute walk \>= 50% of the expected distance; this will not be used as exclusion criteria if due to a reason other than respiratory per judgment of physician e.g., pain
* Ambulatory and resting oxygen (O2) saturation \> 88%
* PPO (predicted post operative)\* forced expiratory volume in one second (FEV1) \>= 50% predicted

  * PPO values should be calculated for each patient
* PPO \* diffusing capacity of the lung for carbon monoxide (DLCO) \>= 50% predicted

  * PPO values should be calculated for each patient
* PPO \* vital capacity \>= 50% predicted

  * PPO values should be calculated for each patient
* Granulocytes \> 1,500 ul
* Platelets \>= 100,000 ul
* Patients must sign a study-specific consent form prior to registration
* Tumor anatomy must allow the isolated lung suffusion in the judgment of the principal investigator (PI)

Exclusion Criteria:

* Uncontrolled intercurrent disease
* Prior chemotherapy for proven metastatic disease within 4 weeks
* Evidence of pulmonary toxicity from previous or ongoing chemotherapy
* Creatinine \> 1.5 mg/dL
* Liver enzymes \> 2 times upper normal
* Uncontrolled congestive heart failure (in judgment of the PI)
* Optional: ejection fraction \< 40% for clinical evidence of insufficient cardiac reserve (multi gated acquisition scan \[MUGA\] or echocardiogram \[ECHO\] will be done only if indicated in the judgment of the PI)
* Myocardial infarction or angina within past 6 months
* Contraindications to anticoagulation
* Hydration intolerance (e.g., uncontrolled congestive heart failure \[CHF\])
* Human immunodeficiency virus positive (HIV+) on antiretroviral therapy
* Pregnant or lactating
* Diffuse pulmonary fibrosis involving over 25% of the total lung parenchyma
* Previous radiation for thorax
* Metastatic sarcoma to lung that is not able to have tumors resected thoracoscopically
* Prior lung removal in the affected lung (would have decreased lung volume)